AbCellera Biologics Inc. (ABCL) Financials

ABCL Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 1.3 billion 192.9 million
Dec. 31, 2025 1.4 billion 215.6 million
Sept. 30, 2025 1.4 billion 392.0 million
June 30, 2025 1.4 billion 395.0 million

ABCL Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -37.4 million 12.0 million
Dec. 31, 2025 -44.6 million 12.9 million
Sept. 30, 2025 -61.5 million 13.9 million
June 30, 2025 -45.8 million 14.2 million

ABCL Net Income

No data available :(

ABCL Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 504.7 million - 134.3 million
Dec. 31, 2025 560.3 million - 137.4 million
Sept. 30, 2025 495.7 million - 142.2 million
June 30, 2025 553.1 million - 142.1 million

ABCL Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 303.1 million
Dec. 31, 2025 298.7 million
Sept. 30, 2025 298.9 million
June 30, 2025 298.5 million

ABCL Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 3.8 million 46.7 million 10.5 million -
Dec. 31, 2025 9.8 million 50.1 million 15.4 million 8.8 million
Sept. 30, 2025 8.9 million 55.0 million 25.0 million 2.9 million
June 30, 2025 13.4 million 39.2 million 22.0 million 3.0 million

ABCL Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 8.3 million 8.7 million
Dec. 31, 2025 44.9 million 7.9 million
Sept. 30, 2025 9.0 million -
June 30, 2025 17.1 million 7.1 million

ABCL Revenue by Segment
Graph available only for paid members. Upgrade to see it.

ABCL

Price: $5.72

52 week price:
1.94
6.52

Earnings Per Share: -0.48 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: Canada

Volume: 1.3 million

Market Capitalization: 1.2 billion

Links: